Real-World Clinical Outcomes and Corticosteroid Tapering in Telitacicept-Based Therapy for Ocular Myasthenia Gravis: An Exploratory Analysis by Prior Treatment History.

Authors

Siyu Xie, Wenli Song, Ran Guo, Chunrong Li, Manman Zhang, Yifan Cheng, Wenting Guo, Bo Jin, Jia Li, Yiqi Wang

Published in

Brain and behavior. Volume 16. Issue 10. Pages e71816.

Abstract

Ocular myasthenia gravis (OMG) is an autoantibody-mediated disease characterized by extraocular muscle weakness. Telitacicept has shown potential in treating autoimmune diseases, but its efficacy and corticosteroid-tapering outcomes in OMG remain unexamined.
This retrospective, multicenter study evaluated the efficacy and corticosteroid-tapering outcomes of telitacicept in 19 OMG patients (11 with refractory OMG and eight with newly/reinitiated treatment OMG). The primary endpoint was the proportion of patients achieving minimal symptom expression (MSE) within 6 months. Secondary endpoints included changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores and reductions in daily prednisone dosage, cumulative response rate (CRR), and short-term tolerability.
Following 6 months of telitacicept treatment, 68.42% of the overall cohort achieved MSE, with the median MG-ADL score significantly decreasing from 3.00 to 0.00 (p < 0.0001). Daily prednisone dosage substantially decreased: the median daily prednisone dose fell from 20.00 to 5.00 mg (p < 0.0001), and 84.21% of patients received prednisone at ≤5 mg/day at month 6. All patients met the predefined initial response criterion within 5 weeks. The refractory and newly/reinitiated treatment groups achieved final MSE rates of 72.7% and 62.5%, respectively, and both groups showed significant reductions in prednisone dependence. This cohort had no serious adverse events.
In this exploratory cohort, telitacicept-based therapy may represent a promising option for OMG, with favorable clinical outcomes, substantial prednisone dose reduction, and acceptable short-term tolerability in patients with different prior treatment histories. Further prospective controlled studies are warranted.

PMID:
42850995
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.